{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Time to Next Therapy is defined as time from the date of enrollment to the date of subsequent antineoplastic therapy.","groups":[{"description":"Ixazomib 4.0 mg, capsules, orally, on Days 1, 8, 15 plus melphalan 6 mg/m\\^2, tablets, orally, on Days 1 to 4 and prednisone 60 mg/m\\^2, tablets, orally, on Days 1 to 4 in 28-day cycle for up to 13 cycles in induction phase followed by ixazomib at dose last tolerated in induction, orally, on Days 1, 8, 15 in 28-day cycle up to 12 cycles or until disease progression or unacceptable toxicity if deriving benefit in maintenance phase (up to 49 maintenance cycles; overall up to 61 cycles \\[58 months\\]).","id":"OG000","title":"Arm B: Ixazomib 4.0 mg (RP2D)"}],"populationDescription":"Time to next therapy was not analyzed due to the change in the planned analysis.","reportingStatus":"POSTED","timeFrame":"From the date of enrollment to the date of subsequent antineoplastic therapy for up to 5.5 years","title":"Time to Next Therapy (Phase 2)","type":"SECONDARY"}